Galectin Therapeutics Inc. is officially headquartered in Norcross, Georgia, within the United States. This primary corporate office serves as the central hub for its executive management team, administrative operations, and strategic oversight of clinical research programs directed at developing groundbreaking therapeutic compounds designed to inhibit galectin-3 proteins for the treatment of severe fibrotic liver diseases and metabolic dysfunctions.